Proprietary Computational Biology Platform: Immuneering's DI-ANN (Disease IMmunEring ANalysis NeTwork) platform integrates vast datasets with computational modeling to identify novel targets and design differentiated small molecule inhibitors, accelerating drug discovery and optimizing therapeutic profiles.

Differentiated RAS/MAPK Pathway Focus: The company uniquely targets historically "undruggable" nodes within the critical RAS/MAPK pathway, aiming to develop first-in-class therapies for a wide range of cancers driven by these mutations where other approaches have struggled.

Novel Mechanism of Action for Lead Asset: IMM-1-104, their lead clinical candidate, employs a differentiated "slow off-rate" MEK inhibition strategy designed to achieve deep and durable tumor regression while allowing for higher, better tolerated dosing, thereby potentially improving the therapeutic window.